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Jumonji domain containing 3
MIR146A
Osteogenesis
Cell differentiationChromatin remodeling is important for cell differentiation. Histone methyltransferase EZH2 and
histone demethylase JMJD3 (KDM6B) modulate levels of histone H3 lysine 27 trimethylation
(H3K27me3). Interplay between the two modulators inﬂuence lineage speciﬁcation in stem cells.
Here, we identiﬁed microRNAMIR146A to be a negative regulator of JMJD3. In the osteogenic differ-
entiation of human mesenchymal stem cells (hMSCs), we observed an upregulation of JMJD3 and a
downregulation of MIR146A. Blocking JMJD3 activity in differentiating hMSCs reduced transcript
levels of osteogenic gene RUNX2. H3K27me3 levels decreased at the RUNX2 promoter during cell dif-
ferentiation. Modulation of MIR146A levels in hMSCs altered JMJD3 and RUNX2 expression and
affected osteogenic differentiation. We conclude that JMJD3 promotes osteogenesis in differentiat-
ing hMSCs, with MIR146A regulating JMJD3.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Posttranslational modiﬁcations of speciﬁc amino acids on his-
tone tails, including methylation and acetylation, are major regula-
tors of gene expression. During stem cell differentiation, histone
modiﬁcations are highly dynamic [1]. In order for cell lineages to
be properly established, methyl or acetyl groups are added, re-
moved, or maintained on histone lysine residues at speciﬁc gene
loci to allow for lineage-speciﬁc gene expression. The establish-
ment and maintenance of methylated histone marks result from
the balance of activity between histone methyltransferases and
histone demethylases. The Polycomb Repressive Complex (PRC2)
is a protein complex associated with gene silencing through the
repressive H3K27me3 mark. Enhancer of zeste homolog 2 (EZH2)
is the catalytic subunit of PRC2 [2]. Its activity is countered by ly-
sine (K)-speciﬁc demethylase 6B (KDM6B), also known as jumonjidomain containing 3 (JMJD3), a histone demethylase capable of
removing methyl groups from H3K27me3 and promoting gene
expression [3–7]. Changes in H3K27me3 distribution are integral
to many types of cell fate transitions, including differentiation
and oncogenesis. These changes are frequently accompanied by
changes in JMJD3 and EZH2 expression [8–10]. Recently, JMJD3
knockdown in mouse embryonic ﬁbroblasts was shown to increase
reprogramming efﬁciency in generating induced pluripotent stem
cells, while EZH2 knockdown decreased efﬁciency [11]. Collec-
tively, these ﬁndings suggest that EZH2 generally promotes ‘stem-
ness’ by acting on pathways associated with pluripotency, while
JMJD3 generally maintains cells in a differentiated state by acting
on genes and pathways associated with differentiation.
As EZH2 and JMJD3 play important roles in inﬂuencing cell fate,
their expression is tightly regulated. The precise mechanisms that
control their expression, however, remain poorly characterized.
MicroRNAs are short non-coding RNAs that inﬂuence a large
number of biological processes. EZH2 is a target of numerous
microRNAs, includingMIR101,MIR26A, andMIR214 [12–14]. While
several microRNAs have been shown to target JMJD3, the
functional consequences of these interactions have not been
determined [15]. Disruption in the regulation of many of these
microRNAs is associated with some cancers, suggesting that
microRNAs may play an important role in regulating the balance
of EZH2 and JMJD3 expression [16].
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cells that can be derived from different sources including bone
marrow, adipose tissue, and umbilical cord. In vitro, hMSCs differ-
entiate into multiple lineages including osteoblasts, chondrocytes,
and adipocytes [17]. While bone marrow-derived MSCs have tradi-
tionally been used to generate osteogenic cells in vitro, numerous
studies have demonstrated that umbilical cord-derived MSCs also
differentiate into osteoblasts under deﬁned culture conditions
[18]. Epigenetic regulation of histone marks is crucial for lineage
speciﬁcation of hMSCs [19–21]. Recently, it was shown that the
inhibition of EZH2 activity through phosphorylation speciﬁcally
promoted hMSC differentiation along the osteogenic lineage [22].
Additionally, JMJD3 promotes osteogenesis in human and mouse
mesenchymal stem cells, as well as the odontogenic differentiation
of dental mesenchymal stem cells [23–25]. This suggests that the
opposing actions of EZH2 and JMJD3 may coordinate hMSC differ-
entiation by regulating the expression of lineage-speciﬁc genes.
However, the mechanisms regulating the expression of EZH2 and
JMJD3 during osteogenic differentiation are unknown. In this cur-
rent study, we discovered that MIR146A inhibits JMJD3 expression
through its interaction with the JMJD3 30UTR. We used human
umbilical cord-derived MSCs to examine how the relative expres-
sion of MIR146A and JMJD3 inﬂuences stem cell fate decisions.2. Materials and methods
2.1. Cell culture
The work described in this article was carried out in accordance
with The Code of Ethics of the World Medical Association (Declaration
of Helsinki) for experiments involving humans (http://www.wma.
net/en/30publications/10policies/b3/index.html), EU Directive
2010/63/EU for animal experiments (http://ec.europa.eu/environ-
ment/chemicals/lab_animals/legislation_en.htm), and Uniform
Requirements for manuscripts submitted to Biomedical journals
(http://www.icmje.org). Human umbilical cord-derived mesenchy-
mal stem cells (hMSCs, ATCC PCS-500-010) were obtained from
the American Type Culture Collection (ATCC, Manassas, VA) and
maintained in Dulbecco’s Modiﬁed Eagle Medium supplemented
with 10% fetal bovine serum (FBS) according to standard protocols.
To induce osteogenic differentiation, hMSCs were cultured in Lon-
za’s osteogenic cell culture media containing 0.5% ascorbic acid,
0.5% dexamethasone and 1% b-glycerophosphate (proprietary cul-
ture media for which the disclosure of molarities is not permitted;
Lonza, Walkersville, MD). For gene expression studies, cells were
differentiated for 3 weeks. The extent of differentiation was as-
sayed by measuring osteocalcin in the media by ELISA, according
to manufacturer’s instructions (Quidel, San Diego, CA). The P19
mouse cell line was maintained in Alpha Minimum Essential Med-
ium supplemented with 10% FBS. Cells were visualized using
brightﬁeld optics on a Leica DMR–HC microscope. Images were
captured using a QImaging Retiga 4000R camera and processed
using Adobe software.
For transfections, hMSCs were re-plated 24 h before transfec-
tion. Pre-miR MIR146A and non-targeting control (NTC) mimics
were purchased from Life Technologies (Grand Island, NY).
MIR146A hairpin inhibitor and non-targeting control (NTC) were
purchased from ThermoScientiﬁc (Wilmington, DE). Full length
JMJD3 expression construct, including the 30 UTR, was obtained
from Addgene (Cambridge, MA; cat #24167) [3]. Transfections
were performed using Lipofectamine 2000 (Life Technologies).
For RNA transfections, approximately 100 pmol of RNA was used.
For vector and RNA co-transfections, hMSCs were transfected with
750 ng of either pCMV-JMDJ3 or pCMV-empty vector together with
20 pmol MIR146A mimic. For transfections with multiple RNAs,50 pmol of each RNA was used. At 24 h after transfection, the med-
ia was changed to osteogenic media. Transfection efﬁciency was,
on average, found to be 64.7% ± 7.59, using a FAM-labeled NTC mi-
mic (n = 17 random ﬁelds of view, SEM). Following transfections,
cells were differentiated for three weeks before RNA or protein
was harvested. P19 cells were transfected using Lipofectamine
2000, 500 ng pMir-JMJD3 Reporter or pMir-JMJD3-mut Reporter,
500 ng pMiR-REPORT b-galactosidase vector (Promega, Madison,
WI), and 20 pmol mimic.
For JMJD3 inhibition, cells were treated with 10 lM GSK-J4 or
vehicle control (0.02% DMSO). Cells were treated for 6 h before
induction of differentiation.
2.2. Luciferase assays
A plasmid vector, pMirTarget, containing the 30UTR of human
JMJD3 (KDM6B, NCBI Reference Sequence: NM_001080424.1)
downstream of the luciferase gene coding region was purchased
from Origene (Rockville, MD; cat #SC213659). We refer to this
plasmid as the pMir-JMJD3 reporter. A second plasmid vector, in
which two nucleotides within the putative MIR146A binding site
of the JMJD3 30UTR were changed (pMir-JMJD3-mut reporter),
was also purchased from Origene (custom order). At 24 h after
transfection, cells were harvested. Luciferase and b-galactosidase
activities were measured using the appropriate enzyme assays, fol-
lowing the manufacturer’s instructions (Promega). Luciferase
activity was normalized to b-galactosidase activity.
2.3. Chromatin immunoprecipitation (ChIP)
The methods of Dahl and Collas were used with modiﬁcations
[26]. Approximately 1  106 cells per chromatin shearing sample
were ﬁxed in 1% formaldehyde (v/v) for 8 min at room tempera-
ture. Chromatin was sheared using a BioRuptor™ NextGen sonica-
tor (Diagenode, Liège, Belgium). Immunoprecipitation was
performed on chromatin using either anti-H3K27me3 antibodies
(cat #07-449; Millipore, Billerica, MA) or anti-IgG control antibod-
ies (Cell Signaling, Danvers, MA). Genomic DNA was precipitated
and ampliﬁed by quantitative real time PCR. Primers used for ChIP
are shown in Supplementary Table 1. Protein enrichment was cal-
culated as a percentage of input.
2.4. Real-time quantitative reverse transcription-PCR (qRT-PCR)
Total RNA was isolated from cells using the RNeasy kit (Qiagen,
Valencia, CA). The quantity and quality of isolated RNA was deter-
mined using the NanoDrop 2000 Spectrophotometer (ThermoSci-
entiﬁc). RNA was reverse transcribed into cDNA using random
hexamer primers and M-MLV reverse transcriptase (New England
Biolabs, Ipswich, MA). For qRT-PCR of transcripts, cDNA was mixed
with Power SYBR Green PCR master mix (Applied Biosystems,
Foster City, CA) and analyzed on an Applied Biosystems 7500 Fast
Real-Time PCR system. Primers are shown in Supplementary
Table 1. For microRNA analysis, total RNA was transcribed into
cDNA using the TaqMan MicroRNA Reverse Transcription Kit (Life
Technologies). MicroRNA-speciﬁc cDNA was then mixed with
TaqMan Universal Master Mix (Life Technologies) and analyzed
on an Applied Biosystems 7500 Fast Real-Time PCR system. Quan-
tiﬁcation of the fold change in gene expression was determined by
the DDCt method.
2.5. Western blot analysis
Cells were harvested and resuspended in RIPA lysis buffer
[50 mM Tris–HCl pH 8.0, 150 mM NaCl, 1% NP-40, 0.5% sodium
deoxycholate, 0.1% SDS] containing protease and phosphatase
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(BioRad, Hercules, CA). 30 lg of total protein was separated by
SDS–PAGE and transferred to polyvinylidene ﬂuoride membranes.
Blots were blocked in 5% milk and incubated overnight with
anti-a-tubulin (cat #sc-5286; Santa Cruz Biotechnology, Santa
Cruz, CA), anti-EZH2 (cat #E9085-02B; US Biological, Salem, MA),
anti-JMJD3 (cat #07-1533; Millipore), anti-EZH2 phospo T487
(cat #ab109398; Abcam, Cambridge, MA), or anti-H3K27me3 (cat
#07-449; Millipore). After washing, blots were incubated with
horseradish peroxide-conjugated secondary antibodies for 1 h at
room temperature. Blots were incubated with a chemiluminescent
substrate, exposed to X-ray ﬁlm, and developed. The full, un-
cropped Western blot of JMJD3 in undifferentiated and differenti-
ating hMSCs is shown in Supplementary Fig. 1.3. Results
3.1. Direct association of MIR146A with the human JMJD3 30 UTR
In silico analysis using the microRNA binding site algorithm
TargetScan predicted human JMJD3 to be a target of numerous
microRNAs, including MIR146A [27]. Previous work by our lab
and others has shown mouse and human MIR146A to be tightly
regulated during adult stem cell differentiation in multiple tissue
types, including spermatogonia, megakaryocytes, erythrocytes,
and macrophages [28–30]. As JMJD3 is an important regulator of
differentiation, we wondered whether MIR146A targeted human
JMJD3 in vitro. To test this, we cloned the JMJD3 30 untranslated re-
gion (UTR) into a luciferase reporter vector. As a negative control,
the predicted MIR146A binding site within the JMJD3 30 UTR was
mutated to alter the sequence by two nucleotides (Fig. 1A). These
luciferase vectors were then co-transfected into P19 cells with a
MIR146Amimic or a non-targeting control (NTC) mimic. We previ-
ously used P19 cells to validate the binding of mouse Mir146a to
the 30 UTR of the mediator complex subunit 1 and they serve as
ideal cells for these assays [28]. Relative to the JMJD3 reporter-
and NTC mimic-transfected condition, cells receiving the JMJD3 re-
porter with the MIR146A mimic exhibited a signiﬁcantly lower
amount of luciferase activity (Fig. 1B). Conversely, cells receiving
a mutated form of the JMJD3 reporter along with the MIR146A mi-
mic did not differ from the control JMJD3 reporter- and NTC mimic-
transfected condition, but had a signiﬁcantly higher amount of
luciferase activity than the cells receiving the non-mutated JMJD3
reporter with the MIR146A mimic (Fig. 1B). Collectively, these re-
sults demonstrate that MIR146A is able to inhibit gene expression
in the presence of the JMJD3 30UTR.
3.2. Downregulation of MIR146A during in vitro hMSC differentiation
To determine the functional relationship of MIR146A and JMJD3
during cell differentiation, we next examined their relative expres-
sion levels in undifferentiated human umbilical cord-derived MSCs
and in hMSCs differentiating down the osteogenic lineage. Stan-
dard protocols for inducing osteogenic differentiation over the
course of three weeks were used. Differentiation was veriﬁed by
measuring levels of osteocalcin in the cell media (Fig. 1C) and by
observing morphological changes (Fig. 1D). Osteocalcin levels in-
creased 2.29-fold in the differentiated hMSC cultures. We also
measured transcript levels of runt related transcription factor 2
(RUNX2), a marker of osteogenic differentiation, and found that
they increased 20.32-fold (Fig. 1E). We then measured MIR146A
transcript levels. Relative to undifferentiated hMSCs, the differenti-
ating cells exhibited a 3.61-fold decrease in MIR146A expression
(Fig. 1F). JMJD3 gene expression increased 3.89-fold in the differen-
tiating hMSCs, while EZH2 levels also increased 2.10-fold (Fig. 1E).We next examined the cells for changes in protein expression.
hMSCs undergoing osteogenic differentiation exhibited an increase
in both JMJD3 and EZH2 protein levels (Fig. 1G). There was also an
increase in EZH2 speciﬁcally phosphorylated at Thr 487, a modiﬁ-
cation which disrupts the binding of EZH2 to components of PRC2,
thereby inhibiting its function (Fig. 1G) [22]. Accordingly, differen-
tiating hMSCs showed lower levels of H3K27me3, suggesting that
the additional EZH2 present was non-functional (Fig. 1G). Taken
together, our results show that MIR146A is downregulated follow-
ing hMSC differentiation. This is accompanied by a concurrent
upregulation of JMJD3 and a global decrease in H3K27me3. This
suggests that an interaction betweenMIR146A and JMJD3may par-
tially regulate the osteogenic differentiation potential of hMSCs.
3.3. JMJD3 promotes the osteogenic differentiation of hMSCs
Following our observation that JMJD3 protein levels increase
during osteogenic differentiation, we next sought to determine
its role in this process. We blocked JMJD3 activity using the speciﬁc
functional inhibitor GSK-J4 [31]. Undifferentiated hMSCs were
treated with either 10 lM GSK-J4 or vehicle control. After a 6 h
treatment period, osteogenic differentiation was then induced. Rel-
ative to the control, hMSCs treated with GSK-J4 showed a signiﬁ-
cant decrease in RUNX2 expression (1.67-fold, Fig. 2A), indicating
that JMJD3 inhibition partially suppressed differentiation. These
results suggest that JMJD3 promotes the osteogenic differentiation
of hMSCs.
We next investigated whether H3K27me3 levels at the promot-
ers of osteogenesis-related genes change when hMSCs differentiate
into osteoblasts. We performed chromatin immunoprecipitation
for H3K27me3 on both undifferentiated and differentiated hMSCs,
and examined the promoter regions of bone morphogenetic
protein 2 (BMP2), SP7 (osterix; OSX) and RUNX2. BMP2 promotes
osteogenesis and is regulated by JMJD3, while SP7 is an osteogen-
esis-speciﬁc transcription factor [25,32]. For all three gene promot-
ers, we saw a signiﬁcant decrease in H3K27me3 enrichment in
differentiated cells compared to undifferentiated hMSCs (Fig. 2B).
Importantly, we did not see a change in H3K27me3 enrichment
at the GAPDH promoter. As an additional control, we examined
downstream regions of the RUNX2 and SP7 genes for changes in
H3K27me3 levels between undifferentiated and differentiating
hMSCs. We did not see altered enrichment (Supplementary
Fig. 2). Collectively, these ﬁndings support the hypothesis that
JMJD3 activity regulates the expression of genes required for osteo-
genesis through a decrease in H3K27me3 levels at their promoters.
3.4. MIR146A expression modulates hMSC differentiation into
osteoblasts
We next determined the biological effect of overexpressing
MIR146A during in vitro hMSC differentiation. hMSCs were trans-
fected with either a MIR146A mimic or an NTC mimic immediately
before inducing osteogenic differentiation. We then examined the
transcript levels of EZH2, JMJD3, and RUNX2 in both NTC mimic-
transfected andMIR146A-transfected cells. While there was no sig-
niﬁcant change in EZH2 expression upon MIR146A overexpression
relative to NTC, MIR146A-transfected cells showed signiﬁcant de-
creases in both JMJD3 (3.02-fold) and RUNX2 (22.08-fold)
(Fig. 3A). We also measured protein levels in the transfected cells.
hMSCs overexpressing MIR146A exhibited a decrease in JMJD3 and
an increase in H3K27me3 (Fig. 3B). Unexpectedly, we saw a slight
increase in EZH2 levels in MIR146A-transfected cells. This suggests
that EZH2 may be regulated by a mechanism independent of
MIR146A. To conﬁrm that the effects of the MIR146A mimic were
speciﬁc, we treated hMSCs simultaneously with a MIR146A mimic
and a MIR146A hairpin inhibitor or an NTC inhibitor before
Fig. 1. MIR146A targets JMJD3 and is downregulated during hMSC differentiation. (A) The nucleotide sequence of theMIR146A binding site within the JMJD3 30UTR. A mutated
version of the binding site (‘JMJD3-mut’) served as a negative control. (B) Plasmid vectors containing the luciferase gene coding region upstream of either the JMJD3 30UTR
(pMir-JMJD3 reporter) or the JMJD3-mut 30UTR (pMir-JMJD3-mut reporter) were cotransfected with a MIR146A mimic or a non-targeting control (NTC) mimic into P19 cells.
The fold change in luciferase activity following MIR146A transfection is shown relative to NTC transfection. (C) Osteocalcin concentration in the cell media was measured by
ELISA. Relative osteocalcin levels are depicted as a fold change in differentiated hMSCs relative to undifferentiated hMSCs. (D) Brightﬁeld images of undifferentiated (top) and
differentiated (bottom) hMSCs at the end of a 21-day differentiation period. Scale bars = 40 lM. (E) Fold change in qRT-PCR transcripts of JMJD3, EZH2, and RUNX2 in
differentiating hMSCs relative to undifferentiated hMSCs. All transcripts were normalized to GAPDH. (F) qRT-PCR of MIR146A in undifferentiated and differentiating hMSCs.
MIR146A transcript levels were normalized to U6 snRNA. (G) Representative western blot showing protein levels of JMJD3, EZH2, EZH2-pT487, and H3K27me3. aTUB was
used as a loading control. All graphs (B, C, E, F) exhibit the mean value ± SEM of 3 biological replicates. ⁄P < 0.05, ⁄⁄⁄P < 0.001; statistical differences were calculated by
Student’s t test.
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Fig. 2. JMJD3 promotes osteogenic differentiation of hMSCs by regulating osteogenic transcription factors. (A) qRT-PCR of EZH2, JMJD3, and RUNX2 following differentiation of
hMSCs treated with either JMJD3 inhibitor GSK-J4 or 0.02% DMSO. The fold change in transcript levels following GSK-J4 treatment is shown relative to vehicle treatment. (B)
Promoter regions of SP7, RUNX2, BMP2, and GAPDH were examined by ChIP using either anti-H3K27me3 antibody or anti-IgG control antibody. Enrichment is presented as
percent of chromatin input. All graphs exhibit the mean value ± SEM of 3 biological replicates. ⁄P < 0.05, ⁄⁄P < 0.01, ⁄⁄⁄P < 0.001; statistical differences were calculated by
Student’s t test.
Fig. 3. Modulation ofMIR146A in hMSCs impacts osteogenic differentiation. (A) Fold change in qRT-PCR transcripts of EZH2, JMJD3, and RUNX2 inMIR146Amimic-transfected
hMSCs relative to NTC mimic-transfected hMSCs. All transcripts were normalized to GAPDH. (B) Representative western blot depicting levels of EZH2, JMJD3, and H3K27me3
in NTC mimic- and MIR146A mimic-transfected cells. aTUB was used as a loading control. (C) Fold change in qRT-PCR transcripts of EZH2, JMJD3, and RUNX2 in MIR146A
inhibitor-transfected hMSCs relative to NTC inhibitor-transfected hMSCs. All transcripts were normalized to GAPDH. (D) Fold change in qRT-PCR transcripts of EZH2, JMJD3,
and RUNX2 in differentiated hMSCs transfected with MIR146A mimic + JMJD3 expression construct pCMV-JMJD3 relative to differentiated hMSCs transfected with MIR146A
mimic + control pCMV empty vector. All transcripts were normalized to GAPDH. All graphs (A, C, D) exhibit the mean value ± SEM of 3 biological replicates. ⁄P < 0.05,
⁄⁄P < 0.01, ⁄⁄⁄P < 0.001; statistical differences were calculated by Student’s t test.
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inhibitor was expected to relieve the effects of the MIR146A mimic
and allow the cells to differentiate normally. Relative to hMSCs
receiving the MIR146A mimic and NTC inhibitor, hMSCs receiving
both the MIR146A mimic and MIR146A inhibitor exhibited an
upregulation of JMJD3 (9.85-fold) and RUNX2 (2.46-fold)
(Supplementary Fig. 3). We conclude that ourMIR146A overexpres-
sion experiments are speciﬁc and that they do not induce off-target
effects.
We next examined the impact of MIR146A inhibition on osteo-
genic differentiation. hMSCs were transfected with a MIR146A
inhibitor or NTC inhibitor immediately before the induction of
osteogenic differentiation. Inhibition of MIR146A signiﬁcantly in-
creased the expression of JMJD3 (3.57-fold) and RUNX2 (5.40-fold)
(Fig. 3C). There was no effect on the transcript levels of EZH2, fur-
ther evidence that EZH2 is not regulated by MIR146A. These resultsdemonstrate that changes inMIR146A expression in differentiating
hMSCs modulate the levels of key transcripts and proteins funda-
mental to osteogenic differentiation. Finally, we wanted to conﬁrm
that the biological impact ofMIR146A on osteogenic differentiation
was speciﬁcally mediated through JMJD3. We modulated JMJD3
expression levels in hMSCs by transfecting them with a JMJD3
expression vector or a control vector together with a MIR146A mi-
mic for 24 h [3]. Osteogenic differentiation was then induced. By
the end of the differentiation period, cells receiving the JMJD3 plas-
mid vector in the presence of the MIR146A mimic exhibited a sig-
niﬁcant increase in the expression of both RUNX2 (2.51-fold,
Fig. 3D), and JMJD3 (1,069-fold, Fig. 3D), whose high levels were
likely due to both the constitutive expression of the vector and
the endogenous expression induced during the differentiation pro-
cess. These ﬁndings indicate that JMJD3 overexpression alleviates
the effects of elevatedMIR146A levels in the cells, and suggest that
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4. Discussion
Multipotent MSCs generate distinct cell types within the mes-
enchymal lineage, including bone, cartilage, and fat [17]. It has be-
come clear in recent years that microRNAs are major regulators of
MSC differentiation, and that they can promote, as well as inhibit,
distinct MSC differentiation pathways [33–36]. In this study, we
have identiﬁed an inhibitory role for MIR146A in regulating the
osteogenic differentiation potential of hMSCs. MIR146A has previ-
ously been shown by our group and others to be highly expressed
in multiple types of adult stem cells, and to play a role in regulating
cell differentiation [28–30]. Collectively, these ﬁndings suggest
that MIR146A may be linked to cell differentiation signaling mech-
anisms. Our current ﬁnding that MIR146A is an inhibitor of JMJD3
expression supports this hypothesis. To determine how MIR146A
ﬁts into the regulatory network of stem cell differentiation, more
work is needed to decipher the control of its expression during dif-
ferentiation processes.
A major feature of MSC differentiation is the extensive chroma-
tin remodeling that occurs upon commitment of the cells to differ-
entiate [19–21]. A recent study found that in adipose-derived
MSCs, lineage speciﬁc promoters lost enrichment of H3K27me3
upon differentiation [37]. When late passage cells that had lost dif-
ferentiation potential were induced to differentiate, they showed a
dramatic upregulation of EZH2 and retained H3K27me3 at speciﬁc
adipogenic gene promoters [37]. This suggests that the loss of
H3K27me3 enrichment at speciﬁc genes is required for the pro-
gression of differentiation. In support of this, JMJD3 has been
shown to be an important regulator of stem cell differentiation.
In mouse neural stem cells and human keratinocytes, differentia-
tion leads to an increase in JMJD3 expression, concurrent with
the loss of H3K27me3 marks at genes important for differentiation
progression [9,38]. During MSC senescence, JMJD3 expression in-
creases, while PRC2 expression decreases [39]. MSC lineage speci-
ﬁcation is accompanied by dramatic epigenetic remodeling,
including changes to PRC2 expression and global H3K27me3 distri-
bution. Here, we have shown that JMJD3 transcript and protein
expression increases signiﬁcantly during hMSC differentiation. A
role for JMJD3 in osteogenesis has also been shown previously in
human and mouse MSCs through its removal of H3K27me3 marks
from key osteogenic genes [23-25]. Collectively, this evidence sup-
ports the hypothesis that JMJD3 upregulation in differentiating
hMSCs ensures that key remodeling events can occur throughout
the differentiation process. In this manner, MIR146A inhibition of
JMJD3 might prevent early differentiation in uncommitted hMSCs.
Despite its involvement in many cellular processes, little is known
about how JMJD3 expression is regulated. To our knowledge, this
report is the ﬁrst to describe a post-transcriptional regulatory
mechanism of JMJD3 control during cell differentiation by a micr-
oRNA. Further investigation into the regulation of JMJD3 expression
will increase our understanding of JMJD3 function and how it
counters the activity of EZH2.
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